EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting O-GlcNAcylated METTL3 impedes MDS/AML progression via diminishing SRSF1 m6A modification

Junjie Gou, Yi Wang, Jingjing Feng, Kaijing Chang, Kexin Wang, Jingjing Bi, Junqi Ge, Chongfu Zhao, Songdi Wu, Zengqi Tan, Feng Guan, Xiang Li

Molecular Therapy · 2025

DOI: 10.1016/j.ymthe.2025.08.042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2025. Verfasst von Junjie Gou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Xi'an No. 1 Hospital, First Affiliated Hospital of Northwest University, School of Medicine, Xi'an, China; Key Laboratory of Resource Biology and Bio…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Methyltransferases, Serine-Arginine Splicing Factors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Innovative Research Group Project of the National Natural Science Foundation of China, Science Fund for Distinguished Young Scholars of Sichuan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N6-methyladenosine (m6A) modification, primarily regulated by methyltransferase-like protein 3 (METTL3), plays a pivotal role in RNA metabolism and leukemogenesis. However, the post-translational mechanisms governing METTL3 stability and function remain incompletely understood. Given the widespread occurrence of O-GlcNAcylation on nuclear and cytosolic proteins, we hypothesized that METTL3 might undergo O-GlcNAcylation, thereby influencing its stability and oncogenic function in myeloid malignancies. In this study, we found that METTL3 is O-GlcNAcylated in both myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), and its expression positively correlates with O-GlcNAcylation levels. Functional assays demonstrated that O-GlcNAcylation enhances METTL3 protein stability and promotes leukemic cell survival. Mechanistically, O-GlcNAcylated METTL3 stabilizes mRNA of serine- and arginine-rich splicing factor 1 (SRSF1), leading to increased expression of the anti-apoptotic protein MCL-1. This, in turn, suppresses apoptosis and supports MDS/AML cell viability. Targeting the O-GlcNAcylated form of METTL3 using a competitive peptide significantly inhibited MDS/AML progression in preclinical models. In conclusion, our findings reveal a novel O-GlcNAcylation-dependent mechanism that regulates METTL3 stability and oncogenic activity through the m6A-SRSF1-MCL-1 axis, highlighting a potential therapeutic strategy for MDS and AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteMyelodysplastic SyndromesMethyltransferasesSerine-Arginine Splicing FactorsAdenosineAcetylglucosamineHumansAnimalsMiceDisease ProgressionCell Line, TumorProtein Processing, Post-TranslationalGlycosylationApoptosisMale

Stichwörter der Autor:innen

AMLIGF2BP2MCL-1MDSMETTL3O-GlcNAcSRSF1gene splicingm(6)A modificationtargeted therapy

Substanzen

MethyltransferasesMETTL3 protein, humanSerine-Arginine Splicing FactorsAdenosineN-methyladenosineAcetylglucosamine

Autor:innen und Institutionen

  • Xi'an No. 1 Hospital, First Affiliated Hospital of Northwest University, School of Medicine, Xi'an, China; Key Laboratory of Resource Biology and Biotechnology of Western China, Ministry of Education, Provincial Key Lab…
  • Department of Hematology, Provincial People's Hospital, Xi'an, China.
  • Key Laboratory of Resource Biology and Biotechnology of Western China, Ministry of Education, Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an, China.
  • Xi'an No. 1 Hospital, First Affiliated Hospital of Northwest University, School of Medicine, Xi'an, China.
  • Key Laboratory of Resource Biology and Biotechnology of Western China, Ministry of Education, Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an, China. Electronic address:…

Förderung

  • National Natural Science Foundation of China
  • Innovative Research Group Project of the National Natural Science Foundation of China
  • Science Fund for Distinguished Young Scholars of Sichuan Province

Zitieren

APA

Gou, J., Wang, Y., Feng, J., Chang, K., Wang, K., Bi, J., Ge, J., Zhao, C., Wu, S., Tan, Z., Guan, F., & Li, X. (2025). Targeting O-GlcNAcylated METTL3 impedes MDS/AML progression via diminishing SRSF1 m6A modification. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.08.042

Vancouver

Gou J, Wang Y, Feng J, Chang K, Wang K, Bi J, et al. Targeting O-GlcNAcylated METTL3 impedes MDS/AML progression via diminishing SRSF1 m6A modification. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.08.042

BibTeX
@article{Gou2025,
  author = {Gou, Junjie and Wang, Yi and Feng, Jingjing and Chang, Kaijing and Wang, Kexin and Bi, Jingjing and Ge, Junqi and Zhao, Chongfu and Wu, Songdi and Tan, Zengqi and Guan, Feng and Li, Xiang},
  title = {Targeting O-GlcNAcylated METTL3 impedes MDS/AML progression via diminishing SRSF1 m6A modification},
  journal = {Molecular Therapy},
  year = {2025},
  doi = {10.1016/j.ymthe.2025.08.042}
}
Kostenlos starten →